Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 9/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 4/20 | 0.52 |
| ▸ | NMUR1 | Q9HB89 | 3/20 | 0.52 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064503 | 0.87 | OPRK1 (0.58) | GNRHROPRM1OPRD1 | |
| SCHEMBL30974464 | 0.82 | SLC6A2 (0.58) | — | |
| Reltecimod SCHEMBL29430066 | 0.82 | CXCL8 (0.53) | EPHA2CXCL8NPY1R | |
| SCHEMBL30788009 | 0.81 | NMUR2 (0.53) | NMUR2NMUR1 | |
| SCHEMBL30476536 | 0.80 | NTSR2 (0.57) | — | |
| SCHEMBL3204375 | 0.79 | OPRK1 (0.59) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL3204393 | 0.79 | OPRK1 (0.59) | NMUR2NMUR1OPRM1OPRD1 | |
| SCHEMBL32670190 | 0.79 | OPRK1 (0.61) | GNRHRNMUR2NMUR1OPRD1 | |
| SCHEMBL29679944 | 0.79 | CALCRL (0.56) | — | |
| SCHEMBL29754576 | 0.79 | BACE1 (0.54) | OPRM1NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | CAMURUS AB (SE) | 2025-11-13 | — | — | US | disclosed |
| US-12257282-B2 | Mixtures and formulations | CAMARUS AB (SE) | 2025-03-25 | — | — | US | disclosed |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | CAMURUS AB (SE) | 2023-09-14 | — | — | US | disclosed |
| US-20220257694-A1 | MIXTURES AND FORMULATIONS | CAMURUS AB (SE) | 2022-08-18 | — | — | US | disclosed |
| EP-3236937-B1 | CONTROLLED-RELEASE FORMULATIONS | CAMURUS AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | CAMURUS AB (SE) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11241476-B2 | Mixtures and formulations comprising an alkyl ammonium EDTA salt | PHOSPHO1, LIPA, ABHD16A | GNRHR 3073/4885EPHA2 3390/4885NMUR2 4347/4885 |
| US-20220257694-A1 | MIXTURES AND FORMULATIONS | PHOSPHO1, LIPA, SGMS1 | GNRHR 3343/4885EPHA2 2586/4885NMUR2 4084/4885 |
| US-20230285502-A1 | MIXTURES AND FORMULATIONS | PHOSPHO1, LIPA, SGMS1 | GNRHR 3343/4885EPHA2 2586/4885NMUR2 4084/4885 |
| US-12257282-B2 | Mixtures and formulations | PHOSPHO1, TTPA, LIPC | GNRHR 3776/4885EPHA2 1509/4885NMUR2 4733/4885 |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | PHOSPHO1, LIPA, ABHD16A | GNRHR 3066/4885EPHA2 3544/4885NMUR2 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.